Not that I am aware of as he is still listed as "Interim" .... seems strange - maybe they anticipate appointing someone else when something they have planned materialises / is signed off ? Perhaps GG has recommended someone for the role that is better equipped to deal with the USA demographic after an FDA approval ?
As far as the follow on documentation for the Warrant Prospectus related to the convertible notes issued today goes subsequent to the 30th Sept ASX announcement to the market, I would anticipate that the FDA want official confirmation that Mesoblast can afford to fund further manufacturing and staffing levels should they issue an approval ? Who knows but the shorters now definitely know if Remestemcel-L is approved there is no CR on its way
GLTAH
MSB Price at posting:
$1.35 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)